LifeCell Corp., of Branchburg, N.J., appointed Bruce Lamb senior vice president, development, regulatory affairs and quality.

Lifeline Therapeutics Inc., of Denver, appointed James Crapo to its board.

MAP Pharmaceuticals Inc., of Mountain View, Calif., appointed Stephen Shrewsbury vice president, clinical and regulatory affairs.

MedImmune Inc., of Gaithersburg, Md., appointed George Milne to its board.

MIV Therapeutics Inc., of Vancouver, British Columbia, appointed Dean-Mo Liu chief scientist, drug delivery technologies.

MPM Capital LP, of Boston, promoted William Greene to general partner.

Neurorecovery Inc., of Tuscaloosa, Ala., appointed Ben Labry and James Terwilliger to oversee business development and marketing activities.

Nonlinear Dynamics, of Newcastle Upon Tyne, UK, appointed Philippe Board strategic marketing manager.

Phylogica, of Perth, Australia, appointed Greg Pullen chief operating officer.

Prosidion Ltd., of Oxford, UK, appointed Jonathan Rachman vice president of clinical development.

Qualyst Inc., of Research Triangle Park, N.C., appointed Andrew Chu director of business development.

Replidyne Inc., of Louisville, Colo., appointed Peter Letendre chief commercial officer.